Mr. Kellogg served as Executive Vice President and Chief Corporate Strategy Officer of Celgene Corporation, or Celgene, a global biopharmaceutical company, from 2018 to 2019, and previously served as Executive Vice President and Chief Financial Officer of Celgene from 2014 to 2018. Prior to that, Mr. Kellogg was Chief Financial Officer and Executive Vice President of Merck & Co. Inc., a global biopharmaceutical company, from 2007 to 2014. From 2000 to 2007, Mr. Kellogg served as Executive Vice President, Finance and Chief Financial Officer at Biogen, Inc., a biotechnology company. Before that, he served as Senior Vice President, PepsiCo E-Commerce at PepsiCo Inc., a global food and beverage company, from March to July 2000 and as Senior Vice President and Chief Financial Officer, Frito-Lay International, a snack food manufacturer, from 1998 to 2000. Mr. Kellogg previously served as a director of Idorsia Ltd. Mr. Kellogg is a proven business, strategic and financial leader who brings to our board over 20 years of experience leading and scaling biotechnology companies and driving strategic transactions. Mr. Kellogg s background includes executive management roles with responsibility for core financial functions, including investor relations, corporate strategy, business development and alliance management. Mr. Kellogg oversaw Biogen s mergers with IDEC (Rituxan share) and Fumapharm (Tecfidera), Merck s acquisition of Schering-Plough (Keytruda), and Celgene s sale to Bristol-Myers Squibb. We believe Mr. Kellogg s financial expertise and experience in strategic transactions and organizational scaling will help drive sustained, profitable growth and financial discipline under our Alnylam 2030 strategy, and position him well to serve as a member of our board and our audit committee, which he chairs.